New Technology for Cervical Cancer Screening
New Technology for Cervical Cancer Screening
复制标题
DOI：
10.1097/igc.0b013e318272e7e7
复制
发表时间：
2012-11-01
影响因子：
4.8
通讯作者：
Li, Xiao-Fu
中科院分区：
文献类型：
--
作者：
Gong, Jiao-Mei;Shen, Yong;Li, Xiao-Fu
背景：宫颈癌是世界范围内女性第二大常见癌症。随着有组织的宫颈细胞学筛查项目的引入，宫颈癌的发病率已大大降低。目的：本研究旨在确定新技术，可以为宫颈癌筛查提供独特的优势。方法：将在PreservCyt中收集的宫颈标本进行ThinPrep细胞学检测，新技术检测和人乳头瘤病毒检测。结果：新技术与ThinPrep细胞学检测的符合率为96.34%，两种方法均阳性931例，阴性148例（kappa = 0.857）。新技术的敏感性和特异性分别为99.04%（931/940）和82.22%（148/180）。Youden指数为0.81。阳性预测值为96.68%（931/963），阴性预测值为94.27%（148/157）。在新技术检测的124例阳性病例中，人乳头瘤病毒DNA检测阳性109例（87.9%），阴性15例（12.1%）。与组织病理学诊断相比，新技术的敏感性和阴性预测值分别为98.57%（69/70）和95.45%（21/22），respectively.Conclusions：筛选设计将使几个竞争的筛查技术在降低宫颈癌的发病率和死亡率的评估。特别是，如果使用新技术作为筛查测试，它可以是快速筛查测试，不依赖于医生的主观判断。因此，它可能为筛选提供独特的优势。
Background: Cervical cancer is the second most common cancer among women worldwide. With the introduction of organized cervical cytological screening programs, the incidence of cervical cancer has been dramatically reduced.Objectives: This study aimed to determine the new technology that can potentially afford unique advantages for cervical cancer screening.Methods: Cervical specimens collected in PreservCyt were processed for ThinPrep cytological test, the new technology test and human papillomavirus detection.Results: The concordance between the new technology and ThinPrep cytological test was 96.34%, with 931 cases positive and 148 cases negative with both tests (kappa = 0.857). The sensitivity and the specificity of the new technology were 99.04% (931/940) and 82.22% (148/180), respectively. Youden index was 0.81. The positive predictive value and the negative predictive value were 96.68% (931/963) and 94.27% (148/157), respectively. In the 124 positive cases of the new technology, human papillomavirus DNA test was positive in 109 cases (87.9%) and negative in 15 cases (12.1%). Compared to the histopathological diagnosis, the sensitivity and the negative predictive value of the new technology were 98.57% (69/70) and 95.45% (21/22), respectively.Conclusions: The screening design will enable evaluation of several competing screening technologies in reducing the incidence of and mortality from cervical cancer. In particular, if the new technology is used as the screening test, it can be a quick screening test and does not depend on the subjective judgment of the doctors. As such, it could potentially afford unique advantages for screening.